Cardiol Therapeutics Accelerates Phase III MAVERIC Enrollment, Targets H2 2026 Readout
Enrollment in Cardiol Therapeutics’ Phase III MAVERIC trial for CardiolRx is accelerating, with completion expected by end-Q2 and top-line data in H2 2026 following FDA Orphan Drug Designation for pericarditis. Phase II results showed pain reduction within two weeks, CRP normalization by 26 weeks and a 71% recurrence-free rate.
1. Phase III MAVERIC Trial Details
Cardiol Therapeutics is evaluating CardiolRx in the Phase III MAVERIC study for recurrent pericarditis. Enrollment is accelerating across leading cardiovascular research centers in the U.S., Europe and Canada, with completion expected by end of Q2 and top-line results anticipated in the second half of 2026.
2. Phase II Efficacy Outcomes
An eight-center Phase II trial demonstrated CardiolRx reduced chest pain to manageable levels within two weeks and sustained improvement at eight weeks. C-reactive protein levels normalized by 26 weeks, and annual pericarditis recurrences fell from 5.8 to 0.9 events, with 71% of patients remaining recurrence-free.
3. ARCHER Myocarditis Results
In the global ARCHER study of myocarditis patients, CardiolRx achieved a highly significant 9.2-gram reduction in left ventricular mass over 12 weeks, alongside favorable trends in extracellular and intracellular volume. These imaging improvements suggest structural benefits in an indication lacking standard therapy.
4. Funding, Orphan Status and Next Steps
The company is fully funded with chemistry, manufacturing and controls readiness and holds FDA Orphan Drug Designation for pericarditis. It is advancing a subcutaneous next-generation candidate (CRD-38) and pursuing strategic partnerships to support commercialization in a potential billion-dollar market.